NS Pharma, Inc. presented 4.5-year safety and efficacy data based on the open-label extension study of brogidirsen (NS-089/NCNP-02) an antisense oligonucleotide for DMD patients with mutations amenable to skipping exon 44. Brogidirsen treatment maintained motor function (NSAA and PUL 2.0) over the 4.5 years and demonstrated an acceptable long-term safety profile.
The post Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy (DMD) Presented at 2026 MDA Clinical & Scientific Conference. appeared first on CureDuchenne.